Preclinical optimization of a broad-spectrum anti-bladder cancer tri-drug regimen via the Feedback System Control (FSC) platform

Therapeutic outcomes of combination chemotherapy have not significantly advanced during the past decades. This has been attributed to the formidable challenges of optimizing drug combinations. Testing a matrix of all possible combinations of doses and agents in a single cell line is unfeasible due t...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Scientific reports 2015-06, Vol.5 (1), p.11464-11464, Article 11464
Hauptverfasser:	Liu, Qi, Zhang, Cheng, Ding, Xianting, Deng, Hui, Zhang, Daming, Cui, Wei, Xu, Hongwei, Wang, Yingwei, Xu, Wanhai, Lv, Lei, Zhang, Hongyu, He, Yinghua, Wu, Qiong, Szyf, Moshe, Ho, Chih-Ming, Zhu, Jingde
Format:	Artikel
Sprache:	eng
Schlagworte:	119/118 13 631/67/1059/2326 631/80/82/23 64/60 Animals Antineoplastic Agents - administration & dosage Antineoplastic Agents - pharmacology Antineoplastic Combined Chemotherapy Protocols - therapeutic use Benign Berries Bladder cancer Cancer Cell Line, Tumor Cell Survival - drug effects Chemotherapy Disease Models, Animal Drug Evaluation, Preclinical - methods Drug Resistance, Neoplasm Drug Therapy, Combination Epithelial cells Feedback Humanities and Social Sciences Humans Mice Models, Theoretical multidisciplinary Science Signal Transduction - drug effects Tumor Burden - drug effects Tumor cell lines Urinary bladder Urinary Bladder Neoplasms - drug therapy Urinary Bladder Neoplasms - metabolism Urinary Bladder Neoplasms - pathology Xenograft Model Antitumor Assays Xenografts
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!